Hematology

Gene therapy for hemophilia shows sustained effect in phase 1/2 study

Updated phase 1/2 data on giroctocogene fitelparvovec (SB-525, or PF-07055480), an investigational gene therapy, showed sustained factor VIII (FVIII) activity level in patients with hemophilia A, according to a statement from Pfizer Inc and Sangamo Therapeutics, Inc. In the Phase 1/2 Alta study, 5 patients with severe hemophilia A who received...